Status:

RECRUITING

A 24-week rPMS Study in Real-world Setting for Enerzair

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Asthma

Eligibility:

All Genders

18-100 years

Brief Summary

This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Enerzair inhalation capsule fo...

Detailed Description

The two different doses of Enerzair inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or mo...

Eligibility Criteria

Inclusion

  • Adult patients (≥18 years of age) with a physician's diagnosis of asthma, who are prescribed Enerzair inhalation capsule (indacaterol acetate/ glycopyrronium bromide/mometasone furoate; 150/50/80, 150/50/160 μg) via Breezhaler, as per the approved label information
  • Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator

Exclusion

  • Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
  • Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
  • Patients participating in other interventional clinical trials

Key Trial Info

Start Date :

May 9 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 11 2027

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT05274425

Start Date

May 9 2022

End Date

March 11 2027

Last Update

January 14 2025

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Novartis Investigative Site

Daegu, Dalseo Gu, South Korea, 42602

2

Novartis Investigative Site

Wŏnju, Gangwon-do, South Korea, 26426

3

Novartis Investigative Site

Bucheon-si, Gyeonggi-do, South Korea, 14584

4

Novartis Investigative Site

Bundang Gu, Gyeonggi-do, South Korea, 13620